Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000927066
$175.35
-6.23% · delayed ~15 min
Last price from Oct 20, 2026
$12.02B market value
From DAVITA INC.'s FY2025 10-K, filed Feb 11, 2026 · read the filing
DAVITA provides healthcare and runs medical facilities. It took in $13.64B last year, which makes it a large company. Of every dollar it sells, about 5 cents is left as profit.
The financial picture is mixed, with profitability and growth needing attention and debt weaker.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score 1.03
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From DAVITA INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Shares in issue
80.5M → 68.5M
Profit
$936.3M → $746.8M
Revenue
$12.82B → $13.64B
Operating margin
16.3% → 15.0%
Measured against FY2024, from the 10-K filed Feb 11, 2026
Improved: -14.9%
80.5M to 68.5MCritical
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
How the latest move compares (quote delayed ~15 min), and what was published around it
DVA fell 6.23% on the latest quote. The average Health Care company tracked here moved +1.53%, and the S&P 500 −1.04%. That is 7.8 points below its sector and 5.2 points below the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 3% a year for the next 10 years. Over the last 10 years it grew by about 4% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 5 cents of every dollar of sales as profit, earning $746.8M last year.
Slowly. Sales grew 6.5% last year.
Manageable, but notable. Clearing its debt would take about 5.1 years of cash flow. For every $1 it owes, it owns $1.07 in assets. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $746.8M and generated $1.89B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 11, 2026Filing for FY2025 | FY202410-K · Feb 13, 2025Filing for FY2024 | FY202310-K · Feb 14, 2024Filing for FY2023 | FY202210-K · Feb 22, 2023Filing for FY2022 | FY202110-K · Feb 11, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $13.64B | $12.82B | $12.14B | $11.61B | $11.62B | +6.5% |
| Selling, general and administrative | $1.67B | $1.54B | $1.47B | $1.36B | $1.20B | +8.8% |
| Operating income | $2.04B | $2.09B | $1.60B | $1.34B | $1.80B | −2.2% |
| Operating marginOperating income ÷ revenueWhat is this? | 15.0% | 16.3% | 13.2% | 11.5% | 15.5% | −1.3 pts |
| Interest expense | $539.9M | $435.2M | $374.0M | $339.2M | $267.0M | +24.1% |
| Income before tax | $1.35B | $1.53B | $1.18B | $966.3M | $1.52B | −12.0% |
| Net income | $746.8M | $936.3M | $691.5M | $560.4M | $978.5M | −20.2% |
| Net marginNet income ÷ revenueWhat is this? | 5.5% | 7.3% | 5.7% | 4.8% | 8.4% | −1.8 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $10.89 | $11.63 | $7.79 | $6.20 | $10.06 | −6.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| DVADAVITA INC. · this page | 4.7/10 | 6/8 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 7,501 shares at $182.34 ($1.4M)
Holds 86,604 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 27,223 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +5.2% · Profit margin +1.6 pts · Earnings per share +54.5% — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following DAVITA INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 735 subsidiaries named in its 10-K, incorporated across 33 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from DVA's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 11, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 4.7 | 6/8 | 10-K, filed Feb 11, 2026 |
| FY2024 | 6.0 | 7/8 | 10-K, filed Feb 13, 2025 |
| FY2023 | 4.7 | 7/8 | 10-K, filed Feb 14, 2024 |
| FY2022 | 3.3 | 5/8 | 10-K, filed Feb 22, 2023 |
| FY2021 | 6.0 | 6/8 | 10-K, filed Feb 11, 2022 |
| FY2020 | 6.0 | 5/8 | 10-K, filed Feb 12, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
1.03
In the distress zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -20.2%
$936.3M to $746.8MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +6.5%
$12.82B to $13.64BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: −1.3 pts
16.3% to 15.0%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −1.8 pts
7.3% to 5.5%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -10.6%
$1.47B to $1.31BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -6.3%
$11.63 to $10.89Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +10.8%
$9.18B to $10.16BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -14.9%
$794.9M to $676.4MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 4, 2026 — read it.
Improved: +54.5%
$2.69 to $4.15Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -13.8%
74.2M to 64.0MCritical
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Improved: +33.1%
$199.3M to $265.4MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +5.2%
$3.38B to $3.55BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +7.7%
$537.8M to $579.0MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +1.6 pts
5.9% to 7.5%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: +5.8%
$10.08B to $10.66BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -5.6%
$708.4M to $669.0MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 4, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +41.6%
$2.93 to $4.15Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +20.2%
$481.9M to $579.0MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +34.4%
$197.5M to $265.4MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: -5.1%
67.4M to 64.0MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Improved: +2.2 pts
14.1% to 16.3%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +1.7 pts
5.8% to 7.5%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 1% and 5%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 13 analysts covering this company, as of . Their views, not this site's.
Of 13 analysts publishing on this company, 1 say strong buy, 6 say buy, 5 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 7.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 14.8x — investors pay $14.8 for each $1 of trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 6.5% |
| 5.5% |
| 16.10x |
| -25.07x |
| DGXQUEST DIAGNOSTICS INC | 8.0/10 | 8/9 | 11.8% | 9.0% | 27.22x | 1.26x |
|---|
| LHLABCORP HOLDINGS INC. | 7.0/10 | 8/9 | 7.2% | 6.3% | 30.94x | 1.13x |
|---|
| Median of peers | 7.5/10 | — | 9.5% | 7.6% | 29.08x | 1.20x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Was granted or awarded shares — 278 shares
Holds 278 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 2,949 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 8,091 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 5,970 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 278 shares after this filing.
Was granted or awarded shares — 278 shares
Holds 6,883 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Signed a material agreement · Took on a direct financial obligation · Held a shareholder vote
Quarterly report for Q1 FY2026
Revenue +6.0% · Free cash flow +495.4% · Cash +46.8% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +6.5% · Operating margin −1.3 pts · Shares in issue -14.9% — against FY2024
Read the filingPublished results
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingQuarterly report for Q3 FY2025
Operating margin −1.6 pts · Shares in issue -14.1% · Profit -30.0% — against Q3 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Revenue +6.1% · Profit margin −1.1 pts · Cash +70.1% — against Q2 FY2024
Read the filingPublished results
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingHeld a shareholder vote
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingReported another event
Read the filingReported another event
Read the filingQuarterly report for Q1 FY2025
Operating margin −2.1 pts · Free cash flow turned positive · Shares in issue -14.0% — against Q1 FY2024
Read the filingThe first 40 of 735. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-11. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
Yahoo ·
Outpatient & specialty care stocks Q2 teardown: DaVita (NYSE:DVA) vs the rest
Yahoo ·
DaVita Earnings Preview: What to Expect
Yahoo ·
DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice
Yahoo ·
Why DaVita (DVA) Stock Is Nosediving
Yahoo ·
S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall
ChartMill ·
S&P 500 Unusual Volume Movers for October 20
ChartMill ·
S&P 500 Top Movers: Gainers and Losers From Today's US Session
ChartMill ·
Health Care Stocks Hit Record Highs, GM Drops Nearly 8%: Stock Market Today
Benzinga ·
'HHS releases new kidney care plan' - Axios Exclusive
Benzinga ·
DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call
Yahoo ·
DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know
Yahoo ·
Primary sources and further research